Vaishali Pharma Limited (NSE:VAISHALI)

Market Cap	1.05B -34.6%
Revenue (ttm)	1.17B +17.6%
Net Income	-5.09M
EPS	-0.05
Shares Out	130.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	74,215
Average Volume	157,067
Open	8.13
Previous Close	7.95
Day's Range	7.96 - 8.13
52-Week Range	7.40 - 17.25
Beta	-0.27
RSI	41.24
Earnings Date	Feb 13, 2026

About Vaishali Pharma

Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti–malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 27
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: VAISHALI

Financial Performance

In fiscal year 2025, Vaishali Pharma's revenue was 990.26 million, an increase of 14.77% compared to the previous year's 862.80 million. Earnings were 8.17 million, an increase of 13.70%.